Analyst Upgrades

• Cree (CREE) and Rubicon Technology (RBCN) to buy from neutral at Merriman.
• Children's Place (PLCE) to outperform from market perform at BMO Capital.
• Lockheed Martin (LMT) to neutral from underperform at BofA/Merrill.
• Copano Energy (CPNO) to outperform from market perform at Morgan Keegan.
• Motorola Mobility (MMI) to neutral from reduce at Nomura.
• Parker-Hannifin (PH) to buy from hold at KeyBanc.
• Akamai (AKAM), ShoreTel (SHOR), AMB Property (AMB) and ProLogis (PLD) to buy from hold at Stifel Nicolaus.

Continue reading Analyst Calls: AAPL, AEO, CREE, DELL, HPQ, IBM, LMT, MMI, MYGN, PH ...

Analyst Calls: AAPL, AEO, CREE, DELL, HPQ, IBM, LMT, MMI, MYGN, PH ... originally appeared on BloggingStocks on Thu, 17 Mar 2011 11:30:00 EST. Please see our terms for use of feeds.

Analyst Upgrades

• Applied Materials (AMAT) to overweight from neutral at Piper Jaffray.
• Air Products (APD) to buy from hold at Citigroup.
• Youku.com (YOKU) and Pinnacle West (PNW) to buy from neutral at Goldman.
• Stryker (SYK) and Zimmer (ZMH) to buy from neutral at UBS.
• Zions Bancorp (ZION) to outperform from neutral at Macquarie.
• Alnylam (ALNY) to buy from hold at Needham.
• AK Steel (AKS) to buy from hold at KeyBanc.

Continue reading Analyst Calls: AEP, AKS, AMAT, EZCH, FRX, LOPE, MYGN, PNW, ZION ...

Analyst Calls: AEP, AKS, AMAT, EZCH, FRX, LOPE, MYGN, PNW, ZION ... originally appeared on BloggingStocks on Wed, 23 Feb 2011 11:40:00 EST. Please see our terms for use of feeds.

Analyst Calls

• Medtronic (MDT) to buy from neutral and 1-800-Flowers.com (FLWS) to neutral from sell at Goldman.
• CarMax (KMX) to outperform from perform at Oppenheimer.
• Points International (PTSEF) to buy from neutral at Merriman.
• Nokia (NOK) to market perform from underperform at Morgan Keegan.
• Amdocs (DOX) to overweight from equal weight at Barclays.
• Western Alliance (WAL) to outperform from sector perform at RBC Capital.
• Carbo Ceramics (CRR) to outperform from market perform at BMO Capital.
• Rackspace (RAX) to buy from hold at Benchmark Co.
• Brinker (EAT) to equal weight from underweight at Morgan Stanley.

Continue reading Analyst Calls: BP, EAT, JBLU, KMX, MDT, MYGN, NOK, NTRS, RAX, RDS.A, T ...

Analyst Calls: BP, EAT, JBLU, KMX, MDT, MYGN, NOK, NTRS, RAX, RDS.A, T ... originally appeared on BloggingStocks on Fri, 28 Jan 2011 11:20:00 EST. Please see our terms for use of feeds.

"Myriad Genetics (MYGN) is an innovative company that can diagnose your risk of cancer years before you have any symptoms," notes growth stock expert Lou Basenese.

The editor of White Cap Research explains, "Even better, it benefits from no competition and one of the best research and development teams around.

"Myriad Genetics' main product is called BRACAnalysis, which is a test that analyzes a woman's genetics to determine her likelihood of developing breast and ovarian cancers. Plain and simple, the test saves lives ... and money.

Continue reading Myriad Genetics (MYGN): Speculating on Cancer Diagnosis

Myriad Genetics (MYGN): Speculating on Cancer Diagnosis originally appeared on BloggingStocks on Fri, 19 Nov 2010 13:00:00 EST. Please see our terms for use of feeds.

Analyst Upgrades

• Piper Jaffray upgraded Duoyuan Global Water (DGW) to neutral from underweight, citing the potential for positive fundamental news flow through the end of the year, and upped its price target to $16 from $9.
• Jefferies upgraded Alcatel-Lucent (ALU) to buy from underperform, expecting a benefit from a significant ramp in EVDO software sales as mobile data growth accelerates.
• Myriad Genetics (MYGN) was upgraded at RBC Capital to outperform from sector perform with a $23 price target based on valuation and potential to be acquired.
• Goldman upgraded Mohawk (MHK) to neutral from sell with a $53 price target.
• Smithfield Foods (SFD) was upgraded to outperform from market perform at BMO capital with a $21 target.
• Priceline.com (PCLN) was upgraded to outperform from market perform at Morgan Keegan.

Continue reading Analyst Calls: ALU, BIG, COST, DGW, DOW, FO, GE, HON, MGM, MYGN, MON ...

Analyst Calls: ALU, BIG, COST, DGW, DOW, FO, GE, HON, MGM, MYGN, MON ... originally appeared on BloggingStocks on Wed, 13 Oct 2010 12:00:00 EST. Please see our terms for use of feeds.

Here are some highlights from this past week's earnings coverage on BloggingStocks:

• American International Group Inc. (AIG) said its Q1 earnings doubled, easily topping analysts' expectations.
• Cablevision Systems Corp. (CVC) said Q1 revenue grew, but disappointing earnings dragged down shares.
• Chevron Corp. (CVX) had strong Q1 earnings and boosted its dividend, but Gulf spill concerns weighed on shares.
• CVS Caremark Corp. (CVS) Q1 earnings topped consensus estimates but it also said same-store sales slipped.
• Freddie Mac (FRE) said its lost $8 billion in Q1, less than a year ago, and requested further bailout funds.

Continue reading Earnings Highlights: AIG, Chevron, Freddie Mac, Kraft Foods, Playboy, Visa ...

Earnings Highlights: AIG, Chevron, Freddie Mac, Kraft Foods, Playboy, Visa ... originally appeared on BloggingStocks on Sat, 08 May 2010 11:40:00 EST. Please see our terms for use of feeds.

Tuesday, Myriad Genetics (MYGN) announced weaker-than-expected quarterly sales and forecast full-year earnings below the expected $1.50 per share and revenue well below the expected $382 million.

Wednesday, the stock felt the ire of spurned investors and disgruntled brokerages. MYGN is more than 25% lower as a four brokerages (at last count) cut their ratings on the firm.

Continue reading Myriad Genetics Plummets on Forecast

Myriad Genetics Plummets on Forecast originally appeared on BloggingStocks on Wed, 05 May 2010 12:00:00 EST. Please see our terms for use of feeds.

Continue reading Myriad Genetics Drops on Patent Ruling

Myriad Genetics Drops on Patent Ruling originally appeared on BloggingStocks on Tue, 30 Mar 2010 13:30:00 EST. Please see our terms for use of feeds.

Analyst upgrades:

• Janney Montgomery upgraded Aqua America (NYSE: WTR) to Buy from Neutral on valuation, viewing the recent weakness as a buying opportunity. The firm has a $19 target on the stock.
• UBS upgraded Gildan Activewear (NYSE: GIL) to Buy from Neutral due to customer Broder's improved liquidity and the improved outlook for margins.
• RBC Capital upgraded State Street (NYSE: STT) to Top Pick from Outperform and raised its target to $55 from $40. The analyst said the $2B capital raise addresses TCE ratio concerns and large unrealized losses in the investment portfolio.
• Sherwin-Williams (NYSE: SHW) was upgraded to Overweight from Neutral at JP Morgan.
• Advance Auto Parts (NYSE: AAP) was upgraded to Buy from Underperform at Banc of America/Merrill.
• M&T Bank (NYSE: MTB) was upgraded to Outperform from Market Perform at Bernstein.

Continue reading Analyst upgrades, downgrades and initiations: WTR, GIL, STT, EHTH, AKZOY, MEOH, UTHR and HGG

Analyst upgrades, downgrades and initiations: WTR, GIL, STT, EHTH, AKZOY, MEOH, UTHR and HGG originally appeared on BloggingStocks on Tue, 19 May 2009 11:00:00 EST. Please see our terms for use of feeds.

In The Oberweis Report, growth expert Jim Oberweis. Jr. sees upside for risk-oriented investors in two diagnostics firms: Myriad Genetics (NASDAQ: MYGN) and Thoratec (NASDAQ: THOR).

"Myriad develops molecular diagnostic products focused in the area of predictive caner diagnostics. It currently sells five genetic tests (and just recently announced the launch of a 6th test in December) focused on cancer and women's health.

"The bulk of their revenues currently come from their BRACAnalysis test for breast cancer. This test is the only one of its kind available to detect a faulty version of BRAC genes in women, which has been linked to significantly increased chances of developing breast and ovarian cancers.

Continue reading Diagnostics duo: Myriad (MYGN) and Thoratec (THOR)

Diagnostics duo: Myriad (MYGN) and Thoratec (THOR) originally appeared on BloggingStocks on Tue, 17 Mar 2009 10:30:00 EST. Please see our terms for use of feeds.

Health care has long been considered a recession-resistant business. Given the current economic challenges, it's little surprise that in our survey of favorite stocks for the coming year, a number of leading advisors turned to this classic defensive sector.

In this year's Top Stock Picks from 75 advisors report, we found an intriguing group of medical-related stocks, from speculation in emerging biotech to well-established pharmaceutical firms, and from medical products makers to medical services firms focused on increasing health care efficiency and early disease detection.

Mike Cintolo, editor of The Cabot Market Letter, thinks Myriad Genetics (NASDAQ: MYGN) could be a "big winner in 2009," The company is a lead in the new field of cancer predisposition testing. For Mike's full report, read Top Stock Picks '09: Myriad Genetics.

Chuck Carlson, editor of The DRIP Investor, sees both quality and potential in Bristol-Myers Squibb (NYSE: BMY). For Chuck's full report, read Top Stock Picks '09: Bristol-Myers Squibb.

Continue reading Drug and health care stocks: The right prescription for 2009

Drug and health care stocks: The right prescription for 2009 originally appeared on BloggingStocks on Mon, 05 Jan 2009 15:30:00 EST. Please see our terms for use of feeds.

This post is part of a special annual report -- Top Stock Picks '09 -- in which TheStockAdvisors.com asked 75 leading newsletter advisors to select their favorite investment for the new year.

"My top idea for 2009 is Myriad Genetics (NASDAQ: MYGN)," says Mike Cintolo. In The Cabot Market Letter, he looks at "the leader in the new field of cancer predisposition testing."

"Myriad Genetics five tests on the market (covering colon, breast, ovarian, and skin cancer) that tell a patient if his genes make it more likely that he'll get various types of cancer.

"During the past few quarters, revenues from these tests have risen at a 50% annual clip, and there's no sign of that slowing down.

"The company also has a pharmaceutical division, but it's going to spin that off sometime in 2009. That should be a big positive, as the drug development division carries good potential, but also big-time costs. Once the cancer predisposition testing division is on its own, much of that revenue growth is going to fall to the bottom line.

Continue reading Top Stock Picks '09: Myriad Genetics (MYGN)

Top Stock Picks '09: Myriad Genetics (MYGN) originally appeared on BloggingStocks on Sun, 04 Jan 2009 09:00:00 EST. Please see our terms for use of feeds.

Myriad Genetics (NASDAQ:MYGN) is recently down $5.48 to $42.25 in pre-open trading. MYGN's Flurizan, a treatment for Alzheimer's diseases, had negative Phase 3 results. RBC Capital has a 12-month forward target of $37 on MYGN. MYGN July option implied volatility of 102 was above its 26-week average of 71 according to Track Data, suggesting larger July price movement.

Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com

Option Update; Myriad Genetics volatility Elevated into disappointing Alzheimer's data originally appeared on BloggingStocks on Mon, 30 Jun 2008 13:06:00 EST. Please see our terms for use of feeds.

Myriad Genetics (NASDAQ: MYGN) is recently up $1.52 to $48.15.

MYGN's Flurizan, a treatment for Alzheimer's diseases is expected release top-line results in late soon.

MYGN call option volume of 8,246 contracts compares to put volume of 3,437 contracts. MYGN July option implied volatility is at 118; August is at 92; above its 26-week average of 68 according to Track Data, suggesting larger July price movement.

Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com

Option Update: Myriad Genetics July volatility at 118 into Alzheimer's data originally appeared on BloggingStocks on Wed, 18 Jun 2008 15:00:00 EST. Please see our terms for use of feeds.

MOST NOTEWORTHY: The Small Cap BioTech sector top today's small list of initiations.

• The Bank of America initiated five companies within the Small Cap BioTech sector:
• Myriad Genetics, Inc. (NASDAQ:MYGN), Array BioPharma, Inc. (NASDAQ:ARRY), Nuvelo, Inc. (NASDAQ:NUVO) and Keryx BioPharmaceuticals Inc (NASDAQ:KERX) with Buy ratings
• and Dendreon Corp (NASDAQ:DNDN) with a Neutral rating.

OTHER INITIATIONS:

• Fiserv, Inc. (NASDAQ:FISV) was resumed with a Market Perform at Wachovia on valuation
• and Century Casinos, Inc. (NASDAQ:CNTY) was initiated with a Hold at Morgan Joseph on valuation.

Analyst summaries provided by TheFlyOnTheWall.com (subscription required).

Analyst initiations 11-2-06: Small Cap BioTech sector initiated originally appeared on BloggingStocks on Thu, 02 Nov 2006 12:14:00 EST. Please see our terms for use of feeds.